In a filing, Biomarin Pharmaceutical Inc revealed its EVP, Chief Technical Officer Guyer Charles Greg unloaded Company’s shares for reported $0.35 million on Nov 12 ’24. In the deal valued at $66.37 per share,5,278 shares were sold. As a result of this transaction, Guyer Charles Greg now holds 68,909 shares worth roughly $4.58 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Guyer Charles Greg bought 5,278 shares, generating $350,324 in total proceeds.
Before that, Burkhart Erin sold 714 shares. Biomarin Pharmaceutical Inc shares valued at $64,260 were divested by the GVP, Chief Accounting Officer at a price of $90.00 per share. As a result of the transaction, Burkhart Erin now holds 14,449 shares, worth roughly $0.96 million.
Wolfe Research initiated its Biomarin Pharmaceutical Inc [BMRN] rating to an Outperform in a research note published on November 15, 2024; the price target was $95. A number of analysts have revised their coverage, including William Blair’s analysts, who decreased its forecast for the stock in late October from “an Outperform” to “a Mkt perform”. Bernstein revised its rating on August 20, 2024. It rated BMRN as “an Outperform” which previously was an “a Mkt perform”.
Price Performance Review of BMRN
On Tuesday, Biomarin Pharmaceutical Inc [NASDAQ:BMRN] saw its stock fall -0.57% to $66.43. Over the last five days, the stock has gained 5.13%. Biomarin Pharmaceutical Inc shares have fallen nearly -31.10% since the year began. Nevertheless, the stocks have fallen -28.52% over the past one year. While a 52-week high of $99.56 was reached on 01/08/24, a 52-week low of $61.15 was recorded on 11/19/24. SMA at 50 days reached $67.25, while 200 days put it at $79.70.
Levels Of Support And Resistance For BMRN Stock
The 24-hour chart illustrates a support level at 66.02, which if violated will result in even more drops to 65.61. On the upside, there is a resistance level at 66.95. A further resistance level may holdings at 67.48. The Relative Strength Index (RSI) on the 14-day chart is 51.45, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.48, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 22.29%. Stochastics %K at 84.78% indicates the stock is a selling.
How much short interest is there in Biomarin Pharmaceutical Inc?
A steep rise in short interest was recorded in Biomarin Pharmaceutical Inc stocks on 2024-11-29, growing by 0.38 million shares to a total of 5.75 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-31 was 5.38 million shares. There was a rise of 6.53%, which implies that there is a positive sentiment for the stock.
